Affiliations 

  • 1 School of Pharmacy, International Medical University, 126, Jalan Jalil Perkasa, Bukit Jalil, Kuala Lumpur, Malaysia
  • 2 School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom
  • 3 School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia. dineshsangarran.ramachandram@monash.edu
Inflammopharmacology, 2023 Dec;31(6):3357-3362.
PMID: 37071316 DOI: 10.1007/s10787-023-01200-5

Abstract

BACKGROUND AND AIMS: Vitamin C appears to be a viable treatment option for patients with COVID-19.

METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of vitamin C versus comparative interventions in patients with COVID-19. The outcome of interest was all-cause mortality.

RESULTS: The meta-analysis of eleven trials using a random-effects model revealed significant reduction in the risk of all-cause mortality with the administration of vitamin C among patients with COVID-19 relative to no vitamin C (pooled odds ratio = 0.53; 95% confidence interval 0.30-0.92). Subgroup analysis of studies that included patients with severe COVID-19 also produced findings of significant mortality reduction with the administration of vitamin C relative to no vitamin C (pooled odds ratio = 0.47; 95% confidence interval 0.26-0.84).

CONCLUSION: Overall, evidence from RCTs suggests a survival benefit for vitamin C in patients with severe COVID-19. However, we should await data from large-scale randomized trials to affirm its mortality benefits.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications